Royalty Pharma Plc (RPRX)

Currency in USD
44.65
+0.55(+1.25%)
Closed·
44.57-0.08(-0.17%)
·
Trading near 52-week High
Earnings results expected in 0 days
RPRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
43.9544.93
52 wk Range
29.6644.93
Key Statistics
Prev. Close
44.1
Open
44.31
Day's Range
43.95-44.93
52 wk Range
29.66-44.93
Volume
3.54M
Average Volume (3m)
4.11M
1-Year Change
40.7186%
Book Value / Share
14.84
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RPRX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
48.10
Upside
+7.72%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 6 consecutive years

Royalty Pharma Plc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Royalty Pharma Plc Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Royalty Pharma Plc Earnings Call Summary for Q3/2025

  • Portfolio receipts rose 11% to $814 million in Q3 2025, with strong performance from Voranigo, Tremfya, and Cystic Fibrosis Franchise
  • Royalty Pharma raised full-year 2025 guidance to $3.2-$3.25 billion in portfolio receipts, representing 14-16% growth despite stock declining 0.77% premarket
  • Company deployed $1 billion in capital during Q3 while maintaining strong financial metrics with portfolio cash flow of $657 million and 81% margin
  • CEO Pablo Legorreta emphasized the company's leadership position and best-in-class investment platform in innovative pharmaceutical products
  • Management anticipates minimal royalties from Promacta in 2026 due to generic launches, highlighting potential challenges despite current robust performance
Last Updated: 2025-11-05, 09:12 a/m
Read Full Transcript

Compare RPRX to Peers and Sector

Metrics to compare
RPRX
Peers
Sector
Relationship
P/E Ratio
24.9x4.3x−0.5x
PEG Ratio
−0.790.230.00
Price/Book
4.0x2.6x2.6x
Price / LTM Sales
11.0x2.6x3.3x
Upside (Analyst Target)
9.7%25.2%45.8%
Fair Value Upside
Unlock14.4%6.4%Unlock

Analyst Ratings

9 Buy
0 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 48.10
(+7.72% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
UBS
Buy49.00+9.74%38.00UpgradeJan 30, 2026
Citi
Buy50.00+11.98%48.00MaintainJan 27, 2026
TD Cowen
Buy45.00+0.78%42.00MaintainDec 11, 2025
Morgan Stanley
Buy56.00+25.42%54.00MaintainNov 06, 2025
Goldman Sachs
Buy45.00+0.78%42.00MaintainNov 06, 2025

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 1.75%
Dividend Yield
2.11%
Industry Median 2.38%
Annualized payout
0.94
Paid quarterly
5-Years Growth
+42.13%
Growth Streak

Earnings

Latest Release
Nov 05, 2025
EPS / Forecast
1.17 / 0.9936
Revenue / Forecast
814.00M / 734.92M
EPS Revisions
Last 90 days

RPRX Income Statement

People Also Watch

328.16
ALNY
-0.93%
146.51
GL
-0.30%
230.95
KEYS
+4.26%
94.58
TROW
+2.78%
102.80
PRU
+2.99%

FAQ

What Is the Royalty Pharma (RPRX) Stock Price Today?

The Royalty Pharma stock price today is 44.65

What Stock Exchange Does Royalty Pharma Trade On?

Royalty Pharma is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Royalty Pharma?

The stock symbol for Royalty Pharma is "RPRX."

Does Royalty Pharma Pay Dividends? What’s The Current Dividend Yield?

The Royalty Pharma dividend yield is 2.11%.

What Is the Royalty Pharma Market Cap?

As of today, Royalty Pharma market cap is 25.77B.

What Is Royalty Pharma's Earnings Per Share (TTM)?

The Royalty Pharma EPS (TTM) is 1.75.

When Is the Next Royalty Pharma Earnings Date?

Royalty Pharma will release its next earnings report on Feb 11, 2026.

From a Technical Analysis Perspective, Is RPRX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Royalty Pharma Stock Split?

Royalty Pharma has split 0 times.

What is the current trading status of Royalty Pharma (RPRX)?

As of Feb 09, 2026, Royalty Pharma (RPRX) is trading at a price of 44.65, with a previous close of 44.10. The stock has fluctuated within a day range of 43.95 to 44.93, while its 52-week range spans from 29.66 to 44.93.

What Is Royalty Pharma (RPRX) Price Target According to Analysts?

The average 12-month price target for Royalty Pharma is USD48.10, with a high estimate of USD56 and a low estimate of USD40.86. 9 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +7.72% Upside potential.

What Is the RPRX Premarket Price?

RPRX's last pre-market stock price is 44.30. The pre-market share volume is 1,270.00, and the stock has decreased by 0.20, or 0.45%.

What Is the RPRX After Hours Price?

RPRX's last after hours stock price is 44.57, the stock has decreased by -0.08, or -0.17%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.